Full notification fileGeneral informationNotification NumberB/DE/15/PEI2422Member State to which the notification was sentGermanyDate of acknowledgement from the Member State Competent Authority21/05/2015Title of the ProjectTHOR - Tübingen Choroideremia gene therapy trial open label Phase 2 clinical trial using an adeno-associated viral vector (AAV2) encoding Rab-escort protein 1 (REP1)Proposed period of release:29/07/2015 to 29/10/2015Name of the Institute(s) or Company(ies)University of Tübingen, Department for Ophthalmology, Schleichstraße 12-16, 72076 Tübingen, Germany;
3. Is the same GMO release planned elsewhere in the Community?NoHas the same GMO been notified elsewhere by the same notifier?NoGMO characterizationGMO is a:DNA VirusIdentity of the GMO:The rAAV2.REP1 product consists of a purified recombinant serotype 2 adeno-associated viral vectors (rAAV) encoding the cDNA of human Rab escort protein type 1 (REP1).
Species: Adeno-associated virusInformation relating to the recipient or parental organisms from wich the GMO is derived
European Commission administrative informationConsent given by the Member State Competent Authority:Yes14/12/2015 00:00:00Remarks: